PURPOSE: Finding an intrathoracic or axillary mass in a breast cancer patient should raise suspicion of a pulmonary or mediastinal nodal metastasis or axillary recurrence. Surprisingly, noncaseating epithelioid cell granuloma can be found in this type of lesion, as in sarcoidosis or a sarcoid-like reaction. METHODS: This series included eight breast cancer patients in whom a late sarcoid-like reaction developed: as an intrathoracic lesion in six, and as an ipsilateral axillary lesion in two. The latency period from oncological surgery to the diagnosis of sarcoidosis was 40 months and the average follow-up after the diagnosis of sarcoidosis was 63.38 months. RESULTS: None of the patients suffered relapse or oncological events during the period of this study. CONCLUSION: To avoid misdiagnosis and overtreatment, pathological examination should always be carried out. We do not recommend any specific treatment for sarcoidosis in a breast cancer patient, but routine oncological follow-up is appropriate. A larger series with statistical analysis is necessary to evaluate the prognosis.
PURPOSE: Finding an intrathoracic or axillary mass in a breast cancerpatient should raise suspicion of a pulmonary or mediastinal nodal metastasis or axillary recurrence. Surprisingly, noncaseating epithelioid cell granuloma can be found in this type of lesion, as in sarcoidosis or a sarcoid-like reaction. METHODS: This series included eight breast cancerpatients in whom a late sarcoid-like reaction developed: as an intrathoracic lesion in six, and as an ipsilateral axillary lesion in two. The latency period from oncological surgery to the diagnosis of sarcoidosis was 40 months and the average follow-up after the diagnosis of sarcoidosis was 63.38 months. RESULTS: None of the patients suffered relapse or oncological events during the period of this study. CONCLUSION: To avoid misdiagnosis and overtreatment, pathological examination should always be carried out. We do not recommend any specific treatment for sarcoidosis in a breast cancerpatient, but routine oncological follow-up is appropriate. A larger series with statistical analysis is necessary to evaluate the prognosis.
Authors: Mohamad A Eloubeidi; Robert J Cerfolio; Victor K Chen; Renee Desmond; Sujath Syed; Buddhiwardhan Ojha Journal: Ann Thorac Surg Date: 2005-01 Impact factor: 4.330
Authors: Edwin Roger Parra; Mauro Canzian; Alexandre Muxfeldt Ab Saber; Ricardo Santos Coêlho; Fabiola Gomes Rodrigues; Ronaldo Adib Kairalla; Carlos Roberto Ribeiro de Carvalho; Vera Luiza Capelozzi Journal: Pathol Res Pract Date: 2004 Impact factor: 3.250
Authors: Sara M Tolaney; Yolanda L Colson; Ritu R Gill; Stephanie Schulte; Margaret M Duggan; Lawrence N Shulman; Eric P Winer Journal: Clin Breast Cancer Date: 2007-10 Impact factor: 3.225
Authors: Jacob Chen; Robert Carter; Daniel Maoz; Ana Tobar; Eran Sharon; Franklin Greif Journal: Breast Care (Basel) Date: 2015-04 Impact factor: 2.860
Authors: Hyun Jung Koo; Mi Young Kim; So Youn Shin; Sooyoung Shin; Sung-Soo Kim; Sei Won Lee; Chang-Min Choi Journal: Medicine (Baltimore) Date: 2015-07 Impact factor: 1.889